A Phase 1 Double-Blind, Placebo-Controlled, Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Nipocalimab in Healthy Male and Female Participants
Latest Information Update: 08 Jul 2022
At a glance
- Drugs Nipocalimab (Primary) ; Nipocalimab (Primary)
- Indications Autoimmune haemolytic anaemia; Haemolytic disease of newborn; Myasthenia gravis; Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 05 Jul 2022 Status changed from recruiting to completed.
- 12 Apr 2022 Planned End Date changed from 5 Jul 2022 to 26 May 2022.
- 12 Apr 2022 Planned primary completion date changed from 5 Jul 2022 to 26 May 2022.